Cyclic depsipeptide compound Aglomycin A and application thereof
The cyclic ester peptide compound aglomycin A isolated from the actinomyces agglomeratus was combined with linezolid, which solved the problem of antibiotic resistance and significantly improved the antibacterial activity against drug-resistant bacteria, especially Vancomyces resistance. Enterococcus squid, demonstrates a powerful antibacterial effect.
Patent Information
- Application Number
- CN202411252569.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-06
AI Technical Summary
Antibiotic resistance has led to a slowdown in the development of new antibiotics, the effectiveness of existing antibiotics on drug-resistant bacteria is reduced, and effective treatment methods are lacking.
The cyclic ester peptide compound aglomycin A was found in the actinomyces agglomeratus isolated from Tibet. The structure was identified by HPLC-MS, NMR and other technologies, and combined with linezolid to enhance the antibacterial treatment of drug-resistant bacteria. active.
aglomycin A has significant antibacterial activity against drug-resistant and non-resistant Enterococcus faecium, especially for Enterococcus vancomycin-resistant, and significantly improves the anti-infection ability in in vivo models when combined with linezolid.
Smart Images

Figure CN119019493A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a cyclic ester peptide compound aglomycin A and application thereof. Background Art
[0002] Antimicrobial resistance (AMR) refers to the ability of bacteria to resist one or more antibiotics through evolution and adaptation, making the originally effective drugs ineffective in treating bacterial infections. Currently, about 1.2 million people die each year due to direct infection with drug-resistant bacteria, and it is estimated that by 2050, this number may reach 10 million. [1,2] Therefore, antibiotic resistance poses a huge threat to human health, survival and socioeconomic development.
[0003] The development of new antibiotics is crucial to solving the problem of antibiotic resistance, but the pace of development of new antibiotics has slowed significantly in the past two decades. According to a report by BIO (Biotechnology Innovation Organization), more than 82% of antibiotics were approved before 2000. [3] In view of the increasingly severe drug resistance situation, the development of new antibiotics is imminent.
[0004] Halides have a wide range of applications in the field of pharmaceutical research due to their wide range of biological and chemical activities. The introduction of halogens can enhance the efficacy, stability and bioavailability of drugs. [4] Halogen-containing drugs currently on the market have the following activities: treatment of bacterial infections, such as ciprofloxacin and levofloxacin; treatment of fungal infections, such as fluconazole and itraconazole; anticancer activity, fluorouracil; antihypertensive activity, chlorthalidone, etc.
[0005] Nature is an important source of halides. In the Natural Product Atlas Database (NPAtlas), halides account for about one-fifteenth of all halides. Our research group has developed a discovery strategy specifically targeting halides and used this strategy to screen for halides from an actinomycete Streptomyces agglomeratus that we had previously isolated from Tibet. [5]Potential chlorinated products were found in the fermentation of aglomycin-resistant Enterococcus faecium (VRE). The metabolites were analyzed by HPLC-MS, and the target compound was found to have a typical monochlorinated isotope mass spectrum peak, with the peak intensity ratio of m / z 773 and 775 being about 3:1. It was predicted that the compound might be the active product of the strain. Therefore, we obtained the compound by targeted separation based on the results of LC-MS analysis, and identified it as a new structure cyclic ester peptide compound named aglomycin A by NMR, MS and Marfey reaction, and further explored the anti-VRE activity of the compound.
[0006] Based on this, the present invention is proposed.
[0007] [References]
[0008] 1.Thompson,T.,The staggering death toll of drug-resistantbacteria.Nature 2022.https: / / www.nature.com / articles / d41586-022-00228-x.
[0009] 2. Antimicrobial Resistance, C., Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022, 399(10325), 629-655.
[0010] 3.May,M.,How to fight antibiotic resistance.Nat Med 2023,29(7),1583-1586.
[0011] 4. Benedetto Tiz, D.; Bagnoli, L.; Rosati, O.; Marini, F.; Sancineto, L.; Santi, C., New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on TheirSyntheses and Pharmaceutical Use. Molecules 2022, 27(5).
[0012] 5. Luo Yajun, Sun Hongmin, He Ning, et al. Isolation and antibacterial activity of actinomycetes from nodules and rhizosphere soil of Hippophae rhamnoides L.[J]. Biotechnology Bulletin, 2021, 37(11): 225-236. Summary of the invention
[0013] The present invention firstly relates to a cyclic ester peptide compound aglomycin A, wherein the molecular formula of the compound aglomycin A is: 35 H 45 ClN8O8S, molecular weight: 772; its chemical structure is shown in the following formula (1):
[0014]
[0015] The present invention also relates to a pharmaceutical composition comprising the compound aglomycin A, wherein the pharmaceutical composition comprises: a therapeutically effective amount of the compound aglomycin A and necessary pharmaceutical excipients.
[0016] Preferably, the pharmaceutical composition is used to treat diseases caused by bacterial infection. Preferably, the bacteria include but are not limited to Enterococcus faecium, vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus.
[0017] Furthermore, the pharmaceutical composition further comprises a second antibacterial active substance, and preferably, the second antibacterial active substance is linezolid.
[0018] The present invention also relates to the following applications of the compound aglomycin A:
[0019] (1) Preparation of antibacterial infection drugs, preferably, the bacteria include but are not limited to Enterococcus faecium, vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus;
[0020] (2) Preparing a combination antibacterial infection drug. Preferably, the combination is to use the compound aglomycin A in combination with linezolid; the bacteria include but are not limited to Enterococcus faecium, vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus.
[0021] The beneficial effects of the present invention are:
[0022] (1) A new chlorinated cyclic ester peptide compound, aglomycin A, was obtained by liquid fermentation of Streptomyces agglomeratus using a variety of separation techniques. Aglomycin A has a significant inhibitory effect on Gram-positive bacteria.
[0023] (2) It was first discovered that aglomycin A has strong antibacterial activity against resistant and non-resistant Enterococcus faecium, and also showed strong antibacterial activity against vancomycin-resistant Enterococcus faecium in an in vivo model experiment with the greater wax moth;
[0024] (3) It was found that aglomycin A and linezolid, when used in combination, had strong antibacterial activity against resistant and non-resistant Enterococcus faecium, and also showed strong anti-vancomycin-resistant Enterococcus faecium activity in an in vivo model experiment with the greater wax moth;
[0025] The research results of the present invention suggest that the cyclic ester peptide compound aglomycin A has good application prospect of antibacterial activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 , the chemical structure of Aglomycin A and its 1 H- 1 H COSY (Bold), HMBC (Arrow), and ROESY (Dotted Arrow) related signals.
[0027] Figure 2 、HRMS spectrum of Aglomycin A.
[0028] Figure 3 , MS / MS of Aglomycin A plus sodium ion (m / z 795.2628).
[0029] Figure 4 , Marfey reaction results of the acid hydrolysis products of Aglomycin A and standard amino acid (LN-MeVal).
[0030] Figure 5 , Marfey reaction results of the acid hydrolysis products of Aglomycin A and standard amino acid (L-HPDA).
[0031] Figure 6 , Marfey reaction results of the acid hydrolysis products of Aglomycin A and standard amino acid (L-Pro).
[0032] Figure 7 , Marfey reaction results of the acid hydrolysis products of Aglomycin A with standard amino acids (L-Thr and L-allo-Thr).
[0033] Figure 8 , four possible isomer structures of Aglomycin A: Isomer 1a, Isomer 1b, Isomer 1c, and Isomer 1d.
[0034] Fig. 9, the checkerboard method was used to determine the inhibitory effect of the combined use of aglomycin A and linezolid on vancomycin-resistant Enterococcus faecium.
[0035] Fig.10 , Aglomycin A and linezolid against Enterococcus faecium.
[0036] Fig.11 , the inhibitory activity results of combined use of Aglomycin A and linezolid against Enterococcus faecium.
[0037] Fig.12 , Aglomycin A and linezolid in the in vivo model of Enterococcus faecium infection in Glechoma moth larvae (A: 2.5 mg / kg aglomycin A and 0.5 mg / kg linezolid; B: 1 mg / kg aglomycin A and 1 mg / kg linezolid). DETAILED DESCRIPTION
[0038] Example 1 Strain expansion and fermentation and extraction and purification of fermentation broth
[0039] 1. Fermentation of endophytic actinomycetes (Streptomyces agglomeratus)
[0040] After culturing Streptomyces agglomeratus on ISP2 solid medium at 28°C for 7 days, the cells were transferred to ISP2 solid medium and cultured for another 7 days. 2 The solid culture of 1.87 μg / mL was inoculated into 50 mL of ISP2 liquid medium and cultured at 220 rpm and 28°C for 48 hours to obtain seed solution.
[0041] Streptomyces agglomeratus was fermented in M3 medium. A total of 150 500 mL conical flasks were inoculated with 5 ml of seed solution per flask. The culture was shaken at 28°C for 9 days.
[0042] 2. Purification and concentration of fermentation broth
[0043] The fermentation broth (15 L) of the above strain was centrifuged at 8,000 rpm for 10 min, and the supernatant was collected and treated with D4006 macroporous adsorption resin (column volume 1.5 L). It was washed with 5 L of deionized water until it was almost colorless, and then eluted with 50% ethanol-water for 5 L, 70% ethanol-water for 5 L, and 100% ethanol for 5 L. The eluted solution was vacuum concentrated to obtain the following three components Fr.A (50% ethanol part), Fr.B (70% ethanol part) and Fr.C (100% ethanol part).
[0044] 3. Preparation of a new cyclic ester peptide compound aglomycin A
[0045] The above component Fr.C was further separated by reverse phase medium pressure column chromatography (0min-100min, 25%-100% acetonitrile / water; 100.1min-120min, 100% acetonitrile, flow rate of 5mL / min), and the similar components were combined into the following four parts according to the liquid chromatography-mass spectrometry results: Fr.C1-Fr.C4.
[0046] Fr.C3 was semi-preparatively purified by Agilent 1200 HPLC (YMC-C8, 10 μm, 10×250 mm, 51% acetonitrile / water, 2.5 mL / min), and the eluate was collected according to the retention time and concentrated under reduced pressure to obtain aglomycin A, a compound of formula 1.
[0047] Example 2: Structural Identification of Cyclic Ester Peptide Compound Aglomycin A
[0048] 1. Aglomycin A (Compound 1) is a white powder, easily soluble in methanol;
[0049] High resolution mass spectrometry ( Figure 2 ) shows that the quasi-molecular ion peak is m / z 773.2849 [M+H] + (C 35 H 46 The theoretical calculated value of ClN8O8S is 773.2848, with an error of 0.1ppm), indicating that the molecular formula of compound 1 is C 35 H 45 ClN8O8S, the degree of unsaturation is 17. 1 H and 13 C NMR (DMSO-d6, Table 1) data showed the presence of 6 amides (δ C 159.2–170.4,δ H 6.78-8.26), 1 nitrogen methyl group (δ H 3.07), 10 oxygen or nitrogen substituted methine signals (δ C 46.6–70.3, δ H 2.51–5.22), 1 o-trisubstituted phenyl group [δ C 114.8–142.1,δ H 7.49,d(9.0); 6.73,t(9.0); 7.68,d(7.8)], 1 2,4-substituted thiazole (δ C 168.2,148.7,123.3; δ H 8.37,s). 1There are two active protons (δ H 7.30, s), indicating the presence of one primary amino group.
[0050] Mass spectrometry signal of compound 1 [M+H] + The secondary mass spectrum of m / z 773.2849 showed that the compound had iminium ions 70.066, 86.097 and 85.075, suggesting that the compound may contain proline (Pro), N-methylvaline (N-MeVal) and hexahydropyridazine-3-carboxylic acid (HPDA). 1 H- 1 The H COSY spectrum shows that compound 1 has six spin systems, see Figure 1 , respectively: CH / CH / CH, NH / CH / CH / CH3, CH / CH2 / CH2 / CH2, NH / CH2 / CH2 / CH2 / CH, NH / CH and CH / CH / CH3(CH3). Combined with the HMBC spectrum, H-2-Thr and NH-2-Thr are correlated with C-1-Thr, indicating that the structure contains a serine (Thr); H-2-Pro and H2-3-Pro are correlated with C-1-Pro, verifying that the compound contains a Pro; H-2-HPDA is correlated with C-4-HPDA and C-1-HPDA, and NH-5-HPDA is correlated with C-2-HPDA, further verifying that the structure contains a HPDA; H-2-(N-MeVal) is correlated with C-1-(N-MeVal), and N-CH3-(N-MeVal) is correlated with C-2-(N-MeVal), further indicating that compound 1 contains a N-MeVal; NH2-2′-ACTA is correlated with C-1′-ACTA and C-3′-ACTA, and H-6′-ACTA is correlated with C-1′-ACTA, C-2′-ACTA and C-2-ACTA are related, H-4′-ACTA is related to C-3′-ACTA, H-5-ACTA is related to C-2-ACTA, C-4-ACTA and C-1″-ACTA, thus inferring the presence of 2-(2-amino-3-chlorophenyl)-4-thiazolecarboxylic acid (ACTA) in the structure; H-2-(epoxy-Val) is related to C-1-(epoxy-Val), C-3-(epoxy-Val) and C-5-(epoxy-Val), H-4-(epoxy-Val) is related to C-2-(epoxy-Val) and C-3-(epoxy-Val), and combined with the unsaturation of the compound, it is inferred that the fragment is a 3,4-epoxyvaline (epoxy-Val).
[0051] Based on the secondary mass spectrometry fragment information of compound 1 with sodium ion m / z 795.2628 ( Figure 3) and in HMBC, NH-2-Thr is related to C-1″-ACTA, H-2-HPDA is related to C-1-Pro, H-2-(epoxy-Val) is related to C-1-HPDA, H-2-(N-MeVal) is related to C-1-(epoxy-Val), and H-3-Thr is related to C-1-(N-MeVal), thereby determining that the above amino acid fragments are connected into a ring, and the connection order is [-Thr(ACTA)-Pro-HPDA-(epoxy-Val)-(N-MeVal)-]. The planar structure of compound 1 was thus determined.
[0052] Table 1 Compound 1 1 H and 13 C NMR data
[0053]
[0054] Example 3: Confirmation of the stereochemical configuration of the cyclic ester peptide compound aglomycin A (compound 1)
[0055] 1. Confirmation of the relative configuration of Aglomycin A
[0056] The ROESY spectrum shows that the H-2-Pro of compound 1 is related to H-2-HPDA, which indicates that the peptide bond formed by Pro and HPDA is a cis configuration; in addition, the Δδ Cβ-Cγ The difference was 4.2 ppm, which indicated that the amide bond between Thr and Pro was in trans configuration.
[0057] 2. Confirmation of the absolute configuration of Aglomycin A
[0058] (1) Confirmation of the absolute configuration of the amino acid residues of aglomycin A acid hydrolysis products using the advanced Marfey reaction
[0059] Aglomycin A was hydrolyzed with HCl and then derivatized with L- and D-FDAA reagents, respectively, and then analyzed by LC-MS. By comparing the retention times of LN-Me-Val, L-HPDA, L-Thr, L-allo-Thr, and L-Pro standards derived from L-FDAA or D-FDAA, it was confirmed that the amino acid residues contained in aglomycin A were all in L configuration. Figure 4-7 ).
[0060] Acid hydrolysis and advanced Marfey reaction of Aglomycin A
[0061] Weigh 0.5 mg of compound 1 and dissolve it in 200 μL 6N HCl, seal it, and acid hydrolyze it at 110℃ for 16 hours. The hydrolyzate obtained was divided into two parts and dried under N2. 30 μL of 0.1M NaHCO3 solution was added to one of the acid hydrolyzates, and 30 μL of L-FDAA acetone solution was added, and the reaction was kept at 40℃ for 1 hour. After adding 1M HCl (30 μL) to terminate the reaction, it was diluted with 200 μL acetonitrile. The preparation method of D-FDAA derivatives is the same.
[0062] Weigh 50 μg of standard amino acid, add 30 μL of 0.1M NaHCO3 solution, and add 30 μL of L-FDAA acetone solution, and react at 40°C for 1 hour. Add 1M HCl (30 μL) to terminate the reaction, and dilute with 200 μL of acetonitrile. The preparation method of D-FDAA derivative is the same.
[0063] LC-MS analysis method: Instrument: ACQUITY UPLC Arc system; Detector: SQD2detector Analytical column: Waters ACQUITY UPLC BEH C 18 column (1.7μm, 100×2.1mm); column temperature: 40℃; mobile phase: phase A: 1‰ formic acid-water, phase B: 1‰ formic acid-acetonitrile; isocratic elution: 0~13min, 70% A+30% B; flow rate: 0.3mL / min.
[0064] (2) Confirmation of the absolute configuration of the 3,4-epoxy-Val residue in the aglomycin A peptide compound using quantum chemical calculations
[0065] In addition to the absolute configuration of the amino acids determined above, compound 1 still has four possible diastereoisomers (compounds 1a-1d, Figure 8 ). To simplify the calculation process without affecting the calculation results, we replaced ACTA with acetic acid. Then, we evaluated the four isomers using GIAO NMR calculations and the DP4+ method. 1 H and 13 The chemical shift value of C is closer to the experimental value. In the DP4+ probability statistical analysis, the CMAE value is the smallest with a probability of 99.99% (Table 2). Finally, the absolute configuration of the 3,4-epoxy-Val residue in 1 is determined to be 2S, 3S (corresponding to Figure 8 (a) The structure of compound 1a.
[0066] Table 2. DP4+ probability calculation results for 1a-1d
[0067]
[0068] Quantum chemical calculations
[0069] Macromodel software was used to search for each conformation using the MMFF force field with DMSO as solvent, using the Mixed Torsional Low-Mode sampling algorithm with 100,000 steps, and the threshold was set to 40 kJ / mol. The obtained conformations were further optimized using the semi-empirical quantum chemistry method combined with GFN2-xTB in the xTB program package, and clustered using the molclus program. The retained conformations with relative energies less than 5 kcal / mol were further optimized using Gaussian 16 software at the B3LYP / 6-31G theoretical level. NMR calculations were performed on conformations with relative energies less than 2.5 kcal / mol at the PCM / mPW1PW91 / 6-311+G(d,p) level.
[0070] The unnormalized chemical shift (δu) is calculated according to the following function δu = σ0-σx, where σx is the Boltzmann averaged shielding tensor and σ0 = 188.654 is the shielding constant for the carbon atom of tetramethylsilane (TMS) calculated at the same level of theory as σx. The normalized chemical shift (δs) is calculated using the expression δs = (δu–b) / a, where a and b are obtained by linear regression δu = aδexp+b. The mean absolute error (MAE) is defined as ∑n|δu-δexp| / n. The corrected mean absolute error (CMAE) is defined as ∑n|δs-δexp| / n.
[0071] Example 5: Antibacterial activity of aglomycin A, a cyclic ester peptide compound
[0072] 1. In vitro antibacterial activity of aglomycin A, a novel cyclic ester peptide
[0073] The antibacterial activity of aglomycin A against seven microorganisms, including Enterococcus faecium (ATCC 35667), Staphylococcus aureus (ATCC29213), Escherichia coli (ATCC 25922), Klebsiella pneumoniae (ATCC BAA2470), Acinetobacter baumannii (ATCC19606), Pseudomonas aeruginosa (ATCC 27853) and Candida albicans (ATCC 10231), was evaluated by microplate assay (Table 3). The results showed that compound 1 had good antibacterial activity against Enterococcus faecium (ATCC 35667) and Staphylococcus aureus (ATCC 29213) (MIC = 4-8 μg / mL). Aglomycin A showed no activity against Gram-negative bacteria and fungi, indicating that the compound is a narrow-spectrum antibiotic targeting Gram-positive bacteria.
[0074] Table 3 In vitro antibacterial activity results of compound 1
[0075]
[0076]
[0077] Note: 1-7 are sensitive strains, 8-13 are resistant strains.
[0078] 2. Antimicrobial activity of aglomycin A, a novel cyclic ester peptide, against clinically isolated microorganisms
[0079] Based on the good performance of compound 1 against sensitive strains, the MIC of compound 1 against 6 different types of clinically isolated resistant bacteria was further determined. Compound 1 was able to significantly inhibit the growth of Enterococcus faecium (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) carrying vancomycin resistance genes (Table 3). Nine clinically isolated Enterococcus faecium and Enterococcus faecalis were selected, and 7 clinically used first-line or second-line antibacterial drugs were selected as the control group to further identify the antibacterial activity of compound 1 (Table 4). The results showed that compound 1 had an inhibitory effect on clinical isolates from different tissues, and could still maintain stable antibacterial activity against strains that were highly resistant to ampicillin, gentamicin, vancomycin and daptomycin, especially against vancomycin-resistant Enterococcus faecium, whether it was the VanA genotype or the VanB genotype, it had strong activity. It can be seen that the antibacterial activity of compound 1 is not limited to sensitive strains, and its inhibitory effect on clinical isolates is not inferior to most commonly used antibiotics in clinical practice.
[0080] Table 4 Antibacterial activity of compound 1 against clinically isolated enterococci
[0081]
[0082] 3. Determination of the synergistic antibacterial activity of aglomycin A (compound 1), a novel cyclic ester peptide
[0083] There are not many clinically available antimicrobial drugs for VRE-related infections, and even fewer antimicrobial drugs are available for VRE of the VanA genotype, mainly linezolid and dalfopristin / quinupristin. In order to explore the combined effect of compound 1 and clinically used anti-VRE drugs, the synergistic antimicrobial activity of compound 1 and first-line antibiotics was tested. Based on the principle of the chessboard method, compound 1 was used in combination with linezolid, dalfopristin and quinupristin, respectively, and their antimicrobial activities were evaluated after culturing for the same time. It was found that compound 1 and linezolid had synergistic antimicrobial activity, and the FIC was between 0.375 and 0.5, which greatly reduced the dosage of the two ( Fig. 9 ).
[0084] 4. Evaluation of the antibacterial mode of aglomycin A, a novel cyclic ester peptide compound
[0085] In addition, we explored the antibacterial mode of compound 1 and drew the antibacterial curve of the compound against Enterococcus faecium ( Fig.10 ). Compared with the blank control group, compound 1 can significantly inhibit the growth of Enterococcus faecium. With the increase of concentration, the inhibition time of bacteria gradually increases. However, no matter how the concentration increases, the number of colonies in the culture medium cannot be reduced to 0. According to the antibacterial curve, aglomycin A and the positive control group linezolid have similar effects, and their antibacterial modes are both time-dependent inhibition.
[0086] Similarly, different concentrations of compound 1 and linezolid mixtures were added to the bacterial culture medium, and the number of bacteria in the culture medium was monitored regularly using the same method to draw a synergistic antibacterial curve ( Fig.11 The synergistic combination has a significantly stronger inhibitory effect on bacteria than the single drug, and can reduce the number of colonies by 100 times under the conditions of aglomycin A2×MIC+linezolid 0.5×MIC, which to some extent transforms the two antibacterial compounds into antibiotics with bactericidal activity.
[0087] 5. In vivo antibacterial activity of aglomycin A, a novel cyclic ester peptide
[0088] The in vivo antibacterial activity of compound 1 was evaluated using the E. faecium ATCC 35667-G. mellonella insect model. Fig.12As shown, the survival rate of the larvae in the blank control group was only 30% 72 hours after infection. The use of aglomycin A and linezolid alone could only provide a certain protection within 48 hours after infection, and the 72-hour survival rate was the same as that of the blank control group. The synergistic experimental groups of 2.5 mg / kg aglomycin A and 0.5 mg / kg linezolid, 1 mg / kg aglomycin A and 1 mg / kg linezolid maintained the survival rate at 90% and 70% for up to 120 hours after infection, which was significantly higher than that of the single-drug group. Therefore, the synergistic use of aglomycin A and linezolid can enhance the anti-infection ability against Enterococcus faecium in vivo.
[0089] Finally, it should be noted that the above embodiments are only used to help those skilled in the art understand the essence of the present invention and are not used to limit the protection scope of the present invention.
Claims
1. A cyclic ester peptide compound aglomycin A, wherein the molecular formula of the compound aglomycin A is: C 35 H 45 ClN8O8S, molecular weight: 772; its chemical structure is shown in the following formula (1):
2. A pharmaceutical composition comprising the compound aglomycin A according to claim 1, wherein the pharmaceutical composition comprises: a therapeutically effective amount of the compound aglomycin A and necessary pharmaceutical excipients.
3. The pharmaceutical composition according to claim 2, characterized in that The pharmaceutical composition is used to treat diseases caused by bacterial infection; preferably, the bacteria include but are not limited to Enterococcus faecium, vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus.
4. The pharmaceutical composition according to claim 2 or 3, characterized in that The pharmaceutical composition further comprises a second antibacterial active substance; preferably, the second antibacterial active substance is linezolid.
5. The following uses of the compound aglomycin A according to claim 1: (1) Preparing antibacterial infection drugs; preferably, the bacteria include but are not limited to Enterococcus faecium, vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus; (2) Preparing a combination antibacterial infection drug; preferably, the combination is to use the compound aglomycin A in combination with linezolid; the bacteria include but are not limited to Enterococcus faecium, vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus.
Citation Information
Patent Citations
New antifungal compound preparation method and application
CN1796386A
Synthesis of cyclodepsipeptide compounds having antineoplastic and / or antimicrobial activity
WO2008151306A1
